Project Grant H79TI081581

Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Tufts University School of Medicine a Project Grant of $652,766 (awarded May 1, 2026; completion February 28, 2031) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct the Extended-Release Opioid Use Disorder Treatment in Massachusetts (EXOUD-MASS) study. This research initiative addresses the critical gap between national opioid overdose death rates—nearly 85,000 annually as of June...

The Marion County Sheriff's Office was awarded a $1,524,313 Project Grant from the Bureau of Justice Assistance's (BJA) Comprehensive Opioid, Stimulant, and other Substances Use Program (CFDA 16.838). The grant will fund the "Continuing MAT" program, which aims to provide comprehensive medication-assisted treatment (MAT) services for opioid use disorder to individuals incarcerated at the Marion County Adult Detention Center. Key components include screening all arrestees for opioid use...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $823,809 to the University of Pittsburgh to develop and validate a suite of multidimensional measures of access to Medications for Opioid Use Disorder (MOUD) across U.S. states and the District of Columbia. The primary objectives are to: Create a Small Area Multidimensional MOUD Access (SAMMA) measure suite using public data sources. Validate and...

Summary of Federal Cooperative Agreement Award Akyso Therapeutics, LLC (doing business as The Drug Delivery Co LLC) received a $2.93 million Cooperative Agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop an extended-release buprenorphine implant for treating opioid use disorder (OUD). The award, effective August 1, 2025, through July 31, 2027, supports the development of a bioabsorbable, subcutaneous implant...

Federal Cooperative Agreement Summary ATAI Therapeutics, Inc. received a Cooperative Agreement award of $5.66M from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective August 15, 2025, with a completion date of June 30, 2027. The award funds the optimization and development of non-hallucinogenic 5-HT2A/2C receptor agonists as therapeutics for opioid use disorder (OUD). ATAI will advance two lead chemical series—EGX-J and EGX-I...

The Altarum Institute, in partnership with Faces & Voices of Recovery and Change Matrix, was awarded a $2,500,000 Cooperative Agreement by the U.S. Department of Justice's Bureau of Justice Assistance (CFDA 16.838 Comprehensive Opioid, Stimulant, and other Substances Use Program) to serve as the Category 2A Training and Technical Assistance (TTA) Center for Access to Treatment, Peer Recovery, and other Recovery Support Services. The TTA Center will assist COSSUP grantees and the broader...

Federal Cooperative Agreement Summary Award Overview New York University School of Medicine received a $4.21 million Cooperative Agreement from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded September 15, 2025, and concluding May 31, 2030. The award funds the STAND (Strengthening Buprenorphine Treatment for Individuals in Carceral Settings) trial, a hybrid type 1 implementation-effectiveness randomized controlled trial...

Federal Cooperative Agreement Summary The National Institute on Drug Abuse (NIDA) awarded Friends Research Institute, Inc. a $4.18 million Cooperative Agreement on September 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a patient preference trial comparing extended-release injectable buprenorphine (XR-B) versus sublingual buprenorphine-naloxone (SL-B) for individuals with opioid use disorder re-entering the community from jail. The five-year study,...

Grant Award Summary The Medical University of South Carolina received a $906,000 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and implement a training curriculum for Emergency Psychiatric Assessment, Treatment, and Healing (EMPATH) unit personnel. The project addresses a critical gap in workforce preparedness by creating specialized training focused on acute management of opioid use disorder (OUD), with...

The Connecticut Department of Mental Health and Addiction Services (DMHAS) was awarded a $7,000,000 Project Grant under the Comprehensive Opioid, Stimulant, and other Substances Use Program (COSSUP) by the U.S. Department of Justice's Bureau of Justice Assistance (CFDA 16.838). The grant, effective October 1, 2024 through September 30, 2027, aims to bolster community-based opioid overdose response efforts in Western Connecticut. Key activities include integrating best practices such as...